Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Is a work over rig not a drilling rig. GL
This looks like a good opportunity. Does anyone know why the drill is still delayed. I thought it was meant to be starting a month or so ago?
Lanstead will be losers if IMM
Flops. Surely if they are investing they have reason to believe Lupuzor has a chance?
If I invest it will be a very small amount. There are some trust issues with the ramping that TM spouts. If the phase III data and follow up study showed great promise on efficacy there would be more noise. It looks like the efficacy is very borderline at best. I remember TM saying that lots of pharma were very interested in the phase III data and yet no collaborations?
So perhaps a share price increase on the splitting out of subsidiaries and a very long shot on Lupuzor...GL all
Looks like the general consensus here is that the efficacy of this drug is barely distinguishable from baseline, hence the emphasis on the extension study being about safety. I’ll keep a watch on this and see if they manage to set up a further trial. Lanstead presumably have a plan. Don’t think they would have been sucked in on the info we have seen. Gl
Still no holdings update that explains the massive volume of shares gone through the books!
Us PIs will be the last to know and I’m sure some FCA regs are being broken.
Hi, AZ has provided the 100m loan for full rights for Tudorza and Duaklir. You can see that in the final results RNS in May. Loan to be repaid over 5 years I believe.
The 30% remission can’t be totally ignored. Even if this drug works for a small % of people with Lupus that’s got to be worth something more than 10p.
Agree, I don’t trust TM but if they get a deal with a bigger player to run another p3 trial with different objective it could work. If that fails and they have sold off/spun out their other interests this will not be worth a bean, literally.
All or nothing .
Gl
I remember the big disappointment with the phase 3 trial. I get your sentiment TM is a bit gun hoe with regards to the future statements. The interview with Navid Malik, (on the IMM website) is far better and gives much more info about the drug and its potential. Might be worth a punt. Gl
Anybody with pharma experience have a view on the extended study data. 30% going into remission is good isn’t it? 30% responded also. I find TM’s recent interview confusing. A lot about safety, which is fine, but virtually nothing about the efficacy which surely is what is needed. He mentions about another clinical trial but there isn’t really any meat on the bones. Views welcome! Gl
Oh yes I see the big sells today. Must be Woodford and that’s a big chunk gone....
You may be right, I’ll recheck available info. In the videos I’ve always heard PH talking about ~1,000. As you say sentiment hard to predict. Gl
Well Woodford has apparently not sold anything further. All the holdings RNSs indicate other funds have been selling.
I don’t trust the way this is bouncing around and until Woodford fund is open I am not topping up. He still has 90mil shares according to published info.
In the meantime I noticed the recent big trades to not add up to the changes in holdings announced. There are approx 31m shares that went through the books but have not been accounted for. I think the max notification period is 3 days from the transaction date! So looks dodgy to me.
GL all
I wouldn’t want to speculate on the flow rate. The constant message has been ~1,000bpd generating around $1mil/month. So I think that is what the market expects. If your figure comes out right then I think there will be disappointment! All imo dyor
All good here and a nice rise.
Next news on flow rates will be important. I think the market expects around 1,000-1,100 so above this will be positive, below negative IMO in terms of the SP.
Well 38 to spud any time over the next couple of weeks.
Let’s see where she settles in between. If that well is a success we are looking very very sorted here.
GL all dyor
Thanks guys, sure I agree the RNS today merits a drop. There are some positives too as mentioned.
I also note the sp was around 340 in May and declined to 270 before the RNS today so presume there were indicators. I’m not in this stock but will research into it. Thanks again and GL if you are holding
Noticed the drop today due to reduced forecast, but can’t find reasons for the recent drop from mid June of ~£3.00.
Looks like a good buy?
Can anyone point out the reasons? Thanks
https://woodfordfunds.com/words/blog/fund-suspension-extension/
IF we get flows of around 1,000bpd then MCAP is at only at 3.5x annual revenue. No debt to pay and cash flow being generated would be fair to put us at 15-20p right now on this well alone. So 35p to include future potential is a longer term target.
BUT Can’t blame folks for waiting for the flow rate data. We shall see, loads of potential but as always DYOR. Gl
Yes I think 10p (ish) is a decent support, especially once we hopefully have confirmed flow rates and hope that’s circa 1,000 bpd
Note that the RNS today’s specified that a more detailed plan and update will follow so hopefully that will answer the queries that seem to be on the board today. I think it’s been confirmed that the well was not shut of for the entire period and has flowed sub optimally for some of that time.
Perhaps a sell order being filled. It might jump once complete. Things shaping up very nicely on the fundamental level. Gl